Skip to main content

Table 1 Clinical characteristics of the metastatic melanoma patients

From: Quality assessment of a clinical next-generation sequencing melanoma panel within the Italian Melanoma Intergroup (IMI)

Sample ID Sex I LN MTS cell tumor content (%) Melanoma site Primary tumor syze Regional lymph node status B M U P BRAF Exon 15 mutation by SS BRAF Exon 15 mutation by additional method NRAS Exon 2–3 mutations by SS
#1 M G ~ 70 left lower leg pT3b pN3 3.55 9 Y n.a. WT PNAClamp™ BRAF Mutation Detection Kit: WT NM_002524: c.182A > G p.Gln61Arg
#2 F G > 90 left upper leg pT4b pN3 5.53 11 Y Y NM_004333: c.1799 T > A p.Val600Glu PNAClamp™ BRAF Mutation Detection Kit: Mutated n.d.
#3 M G > 80 right lower leg n.a pN3 2.92 3 n.a N NM_004333:
c.1799 T > A p.Val600Glu
PNAClamp™ BRAF Mutation Detection Kit: Mutated n.d.
#4 F G 80–85 right arm pT4a pN3 12.5 14 Y Y WT PNAClamp™ BRAF Mutation Detection Kit: WT NM_002524: c.181C > A p.Gln61Lys
#5 F G ~ 80 left upper leg pT3a pN3 3.5 5–9 N Y NM_004333: c.1799_1800delTGinsAC p.Val600Asp PNAClamp™ BRAF Mutation Detection Kit: Mutated WT
#6 M S ~ 80 upper back pT3a pN2b 2.75 4 N N NM_004333: c.1799 T > A p.Val600Glu Therascreen™ BRAF Pyro Kit: Mutated WT
#7 M S > 80 left upper leg pT3b pN3b 3.53 5 Y Y NM_004333: c.1798_1799delGTinsAA p.Val600Lys Therascreen™ BRAF Pyro Kit: Mutated WT
#8 F S ~ 80 left forearm pT3a pN2b 2.26 3 N N NM_004333: c.1799 T > A p.Val600Glu Therascreen™ BRAF Pyro Kit: Mutated WT
#9 M S > 80 right lower leg pT4b pN3b 7.45 8 Y N WT Therascreen™ BRAF Pyro Kit: WT WT
#10 F S ~ 90 left foot pT3b pN2b 2.15 2 Y Y NM_004333: c.1790 T > G p.Leu597Arg Therascreen™ BRAF Pyro Kit: Not Detected WT
#11 M S ~ 80 upper back pT3a pN2b 2.84 2 N N NM_004333: c.1799 T > A p.Val600Glu Therascreen™ BRAF Pyro Kit: Mutated WT
  1. Abbreviations: M Male; F female; I institute; G: IRCCS Ospedale Policlinico San Martino, Genoa; S: Unit of Cancer Genetics at the National Research Council/CNR, Sassari; LN MTS lymph node metastases; B Breslow; M mitosis/mm2; U ulceration; P pigmentation; SS sanger sequencing; Y yes; N no; n.a. not available, n.d. not done, WT wild type